VA San Diego Healthcare Systems FDA Form 483
VA San Diego Healthcare Systems FDA Form 483: 11 Inspectional Observations & GMP Lessons
Educational review of FDA observations involving smoke studies, beta-lactam segregation, contamination control, disinfection, aseptic practices, cleanroom equipment, personnel practices, materials and sterile gloves.
⚠️ Educational Disclaimer
This article is provided for educational, GMP awareness and professional learning purposes only.
The information presented here is based on the supplied FDA Form 483 issued following an FDA inspection of VA San Diego Healthcare Systems.
A Form FDA 483 contains inspectional observations. It does not, by itself, represent a final FDA determination regarding the firm's compliance status.
PharmaceuticalMicrobiology.in does not criticize, condemn, defame or make negative judgments about VA San Diego Healthcare Systems, its employees, management, investigators, operators or personnel.
The purpose of this article is to convert publicly available regulatory observations into practical GMP learning points so that other pharmaceutical and sterile-drug organizations can review their own systems and identify potential weaknesses before an inspection.
This page is not legal advice, regulatory certification, a compliance determination or a substitute for reviewing the original FDA document and applicable regulations and guidance.
📋 FDA Inspection Profile
| Firm | VA San Diego Healthcare Systems |
| Location | 3350 La Jolla Village Dr, San Diego, California 92161-0002 |
| Inspection Dates | April 27–May 1, 2026; May 4–6, 2026; May 8, 2026 |
| FEI Number | 2071629 |
| Establishment Type | Producer of Sterile Drug Products |
| FDA Form | Form FDA 483 — Inspectional Observations |
🎯 Why This FDA 483 Is Important for GMP Awareness
The observations in this FDA Form 483 provide a broad learning opportunity covering several critical elements of sterile-drug manufacturing and aseptic processing.
The observations include weaknesses related to dynamic smoke studies, beta-lactam cross-contamination controls, contamination, material transfer, personnel behavior, glove practices, cleanroom surfaces, exposed materials and sterile gloves.
For other pharmaceutical organizations, the most useful question is: “Could a similar weakness exist in our own facility?”
🔎 11 FDA Observations — Quick Navigation
Observation 1 — Smoke Studies Inadequately Performed Under Dynamic Conditions
The FDA observed that smoke studies were not conducted under dynamic conditions simulating worst-case production activities, including the components, materials and equipment present during actual or routine aseptic operations.
The observation covered hazardous BSCs, non-hazardous LAFH equipment, and segregated compounding areas.
What Other Pharmaceutical Organizations Can Learn
- Challenge smoke studies with representative production activities.
- Include relevant materials, equipment and workflow arrangements.
- Evaluate actual operator positioning and interventions.
- Ensure the entire critical workspace is adequately visualized.
- Use sufficient smoke to identify airflow patterns and potential turbulence.
Observation 2 — Beta-Lactam Cross-Contamination Controls
The FDA observed beta-lactam drug products being produced in the same ISO 5 hoods as non-beta-lactam sterile drug products without adequate containment, segregation and/or cleaning controls to prevent cross-contamination.
The observation describes production of several beta-lactam products and identifies concerns regarding the cleaning frequency and controls used between beta-lactam and non-beta-lactam production.
What Other Pharmaceutical Organizations Can Learn
- Assess cross-contamination risks associated with beta-lactam operations.
- Define appropriate segregation and containment controls.
- Establish scientifically justified cleaning procedures.
- Evaluate cleaning frequency and residue-removal capability.
- Ensure personnel understand product-specific contamination risks.
Observation 3 — Contamination Observed in Production Area
The FDA observed unidentified brown staining on a HEPA filter in an ISO 5 non-hazardous LAFH production hood.
The firm was unable to identify the source of the staining or confirm whether it affected filter integrity, air quality or aseptic conditions. The duration of the condition was also unknown.
What Other Pharmaceutical Organizations Can Learn
- Investigate unexplained contamination immediately.
- Assess potential impact on critical equipment and product quality.
- Evaluate HEPA filter integrity where appropriate.
- Document investigation, assessment and corrective actions.
- Establish effective visual inspection and maintenance controls.
Observation 4 — Disinfection of Supplies During Air-Quality Transitions
The FDA identified a lack of disinfection of supplies at transitions from lower-quality air areas to higher-quality air areas.
The observation included materials moving from ISO 7 buffer rooms into ISO 5 critical zones without appropriate disinfection.
The FDA also described concerns involving a reused fluid-discard bottle and a wearable communication device used by operators entering the ISO 5 environment.
What Other Pharmaceutical Organizations Can Learn
- Map every material transfer pathway into ISO 5 areas.
- Define transfer disinfection requirements clearly.
- Assess reusable containers and devices entering critical areas.
- Control personal electronic and communication devices.
- Include transfer practices in aseptic-behavior training.
Observation 5 — Operator's Arms on ISO 5 Work Surface
The FDA observed an operator resting their arms or hands on the ISO 5 work surface during aseptic production.
The observations included hands resting directly on an ISO 5 workbench and elbows resting on the front grille of an ISO 5 Biological Safety Cabinet.
What Other Pharmaceutical Organizations Can Learn
- Train operators on appropriate body positioning.
- Prevent unnecessary contact with critical surfaces.
- Include these behaviors in routine aseptic observations.
- Use media fills and qualification activities to assess operator technique.
Observation 6 — Gloved Hands Contacting Outside Surfaces
Personnel were observed touching equipment or other surfaces outside the ISO 5 area with gloved hands and then continuing aseptic processing without changing or sanitizing gloves.
The FDA specifically described contact with a computer keyboard and mouse in the ISO 7 buffer room before returning to the ISO 5 critical area.
What Other Pharmaceutical Organizations Can Learn
- Identify all surfaces routinely touched during operations.
- Define glove sanitization/change requirements.
- Include keyboards, mice, scanners and workflow equipment in contamination assessments.
- Ensure cleaning responsibilities are clearly assigned.
- Verify actual practice against the SOP.
Observation 7 — Rapid Movement in Critical Area
The FDA observed personnel moving quickly in a critical area in a manner likely to disrupt unidirectional airflow.
The example involved rapid hand movement after spraying gloved hands under the ISO 5 hood, with movement over materials and components during production.
What Other Pharmaceutical Organizations Can Learn
- Train operators in controlled aseptic movements.
- Evaluate hand movement during routine production.
- Include operator movement in smoke-study assessments.
- Assess whether procedures encourage unnecessary movement.
Observation 8 — Difficult-to-Clean and Particle-Generating Surfaces
The FDA identified production-area equipment or surfaces that were difficult to clean, porous, particle-generating or visibly dirty.
The observation included a screw and washer associated with a BSC grille, chipped/protruding paint, uncleaned fire sprinklers and other ceiling-mounted equipment, Bluetooth speakers, and electronic workflow equipment that was not wiped down between batches.
What Other Pharmaceutical Organizations Can Learn
- Inspect cleanrooms for hard-to-clean locations.
- Control particle-generating or damaged surfaces.
- Include ceiling-mounted items in cleaning programs.
- Assess engineering modifications before introducing them into critical areas.
- Define batch-to-batch cleaning of electronic equipment.
Observation 9 — Exposed Hair and Skin During Aseptic Processing
The FDA observed personnel performing aseptic manipulations with exposed hair or skin.
The observation included exposed hair during sterile drug processing and an operator inserting their head, exposed forehead skin and eyeglasses into the ISO 5 critical zone.
What Other Pharmaceutical Organizations Can Learn
- Verify complete gowning compliance.
- Assess operator positioning during actual interventions.
- Evaluate eyeglasses and other personal items entering critical zones.
- Use routine observation programs to verify aseptic behavior.
Observation 10 — Materials Exposed to Lower-Quality Air
The FDA observed materials exposed to air of lower than ISO 5 quality.
The observation described sterile lint-free wipes stored in an exposed, open condition in ISO 7 buffer rooms, including damaged transparent boxes left open during production.
The wipes were subsequently used for ISO 5 cleaning and for materials transitioning into ISO 5 critical areas.
What Other Pharmaceutical Organizations Can Learn
- Control storage conditions of sterile materials.
- Inspect containers and dispensers for damage.
- Prevent unnecessary exposure before use.
- Evaluate material transfer and storage practices.
- Include material exposure in contamination-control strategy.
Observation 11 — Non-Sterile / Expired Sterile Gloves
The FDA observed personnel engaged in aseptic processing wearing gloves that were considered non-sterile.
The observation specifically states that operators used expired sterile gloves during aseptic production and notes that there was no assurance that the gloves remained intact and sterile.
What Other Pharmaceutical Organizations Can Learn
- Control sterile-glove inventory carefully.
- Verify expiry or applicable manufacturer-use requirements.
- Prevent expired materials from entering aseptic operations.
- Include glove integrity and storage in material controls.
- Strengthen line-clearance and pre-use verification.
🧩 What Do These 11 Observations Teach the Pharmaceutical Industry?
The observations can be viewed as an educational opportunity across several connected contamination-control themes.
Dynamic studies should represent real operations.
Product-specific contamination risks require appropriate controls.
Operator actions directly influence the critical environment.
Every transition into a critical zone should be appropriately controlled.
Cleaning systems should cover equipment, materials and frequently touched surfaces.
Cleanroom design should support effective cleaning and contamination control.
✅ 11-Point FDA 483 Self-Assessment for Your Facility
Use the following questions as an internal GMP awareness exercise.
- Are your smoke studies performed under representative dynamic and worst-case operating conditions?
- Do your smoke studies include actual equipment, materials and workflow arrangements?
- Are beta-lactam contamination and segregation controls scientifically justified?
- Can unexplained contamination in ISO 5 areas be immediately identified, investigated and assessed?
- Are all materials appropriately controlled when moving from lower-quality air areas into critical zones?
- Are operators prevented from resting hands, arms or elbows on critical surfaces?
- Are glove-change and glove-sanitization requirements clear and consistently followed?
- Does your aseptic technique program control rapid or unnecessary movement?
- Are cleanroom surfaces, equipment and fixtures genuinely easy to clean and maintain?
- Are personnel gowning and exposed-skin controls consistently verified?
- Are sterile gloves and other sterile materials controlled for expiry, integrity and appropriate use?
🔧 Root Cause Investigation — Look Beyond Retraining
When a similar issue is identified internally, simply retraining the operator may not always address the underlying system weakness.
A robust investigation should consider whether the event may involve:
The objective should be to determine whether the issue is isolated or whether it indicates a broader weakness in the contamination-control strategy or quality system.
⭐ Management & QA Awareness
The most valuable lesson from an FDA Form 483 is not simply to correct the exact event observed by an investigator.
Organizations should ask whether their quality systems are capable of detecting the same type of weakness before an FDA investigator identifies it.
- Can QA observe actual aseptic practices?
- Are smoke studies truly representative?
- Are contamination risks periodically reassessed?
- Are cleaning programs challenged?
- Are operators trained and periodically requalified?
- Are facility and equipment conditions routinely inspected?
- Are CAPA effectiveness checks capable of detecting recurrence?
📌 FDA Form 483 vs. FDA Warning Letter
Important: The supplied document is an FDA Form 483 — Inspectional Observations. It should not be described as an FDA Warning Letter.
A Form 483 documents observations made by FDA investigators during an inspection. The document itself states that these observations do not represent a final Agency determination regarding compliance.
This distinction is important when presenting regulatory information professionally and accurately.
📚 FDA Regulatory Learning Resources
📄 Source Document
This educational review is based on the supplied FDA Form 483 issued to VA San Diego Healthcare Systems, covering an FDA inspection conducted from April 27 through May 8, 2026.
The supplied document contains 11 inspectional observations covering smoke studies, beta-lactam controls, contamination, supply disinfection, operator practices, glove controls, facility/equipment conditions, personnel gowning, material exposure and sterile gloves.
⚖️ Final Educational Disclaimer
For Educational Purposes Only: This article is intended for pharmaceutical microbiology education, GMP awareness, regulatory learning and professional development.
No Criticism or Defamation: PharmaceuticalMicrobiology.in does not intend to criticize, condemn, defame or make adverse judgments regarding VA San Diego Healthcare Systems or any individual associated with the organization.
Inspectional Observations: The information presented is based on observations contained in the supplied FDA Form 483. These observations should not be represented as a final FDA enforcement decision or final determination of compliance.
Independent Review: Readers should review the original FDA documentation and applicable laws, regulations, guidance and quality-system requirements before making compliance or business decisions.
No Legal or Regulatory Advice: Nothing on this page constitutes legal advice, regulatory certification, compliance certification or a formal FDA interpretation.
FDA 483s • FDA Warning Letters • FDA Guidance • GMP • Sterility Assurance • Pharmaceutical Microbiology
Home Disclaimer
Comments
Post a Comment
💬 Share your thoughts or questions about this topic below.
Ask your real microbiology lab problems, deviations, or GMP doubts here.
I personally reply with practical solutions from industry experience.